Early Toxicity Testing Market Size, Share, Industry, Forecast and outlook (2024-2031)

Early Toxicity Testing Market is Segmented By Technique (In-Vivo, In-Vitro (By Assays (Cell-Based ELISA and Western Blots, Enzyme Toxicity Assays, Bacterial Toxicity Assays, Tissues Culture Assays, Receptors Binding Assays, Others), By Toxicity End Points and Tests (Carcinogenicity, Dermal Toxicity, Skin Sensitization and Irritation, Ocular Toxicity, Genotoxicity, Others), In-Silico), By End-User (Pharmaceutical, Food and Beverages, Chemical Industry, Diagnostics, Cosmetics, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031

Report Overview

The Early Toxicity Testing Market is expected to grow at a CAGR of 9.6% during the forecast period 2024-2031.

Toxicity is the degree to which a substance endangers a living creature. During the production of newer molecules, the effects of chemical substances on the body are examined to select a possible therapeutic candidate. Early toxicity testing is performed during the pre-clinical phases of a drug development process. It is critical because toxicity is the top cause of prospective drug candidate failure in the later stages of drug development, resulting in substantial financial losses for companies.

Early Toxicity Testing Market Scope

For more insights - Request Free Sample

Early Toxicity Testing Market Trends

The global early toxicity testing market is predicted to develop significantly over the forecast period, owing to increased R&D activities and strict regulatory bodies concerned with public healthcare welfare. Furthermore, technological developments in vitro approach, an increase in the application of in vitro models in the global early toxicity testing sector, and an increase in the adoption of early toxicity testing in various industries all contribute to market growth.

Rising awareness about early toxicity testing will drive the market growth   

Preclinical toxicity testing investigations are conducted to evaluate the new chemical entity under development to analyze its safety and efficacy in animal models before entering human clinical trials. Approximately 30% of medications tried in clinical trials fail due to unexpected and unacceptable toxicological characteristics. Early toxicity diagnosis during the preclinical phase can save money on clinical studies and avoid needless hazardous chemical exposure to healthy human volunteers participating in clinical trials. As a result, industries participating in the medication development process and regulatory agencies focus on the early identification of chemical toxicity. To this end, toxicity investigations are outsourced to a CRO professional team to expedite the process and save expenses. As a result, the increased emphasis on early toxicity detection will likely boost the worldwide early toxicity testing market during the forecast period.

Furthermore, long-term growth patterns in this sector can be caught by maintaining ongoing process improvements and financial stability to invest in the finest tactics. Furthermore, technological advancements in vitro methods, an increase in the usage of in vitro models in the worldwide early toxicity testing sector, and an increase in early toxicity testing in various industries all contribute to market growth. Leading players throughout the world are focusing their efforts on technological advancements to boost market growth. Technological advancements in early toxicity testing will generate chances for the early toxicity testing market to develop during the forecast period. These factors are likely to boost the Early Toxicity Testing market.

Difficulties associated with preclinical testing are likely to hamper the market growth 

However, difficulties associated with preclinical testing impede the growth of the worldwide early toxicity testing market. Furthermore, firms conduct early toxicity testing to meet government regulations for marketing the drug, which is regarded as a growth-restricting factor. The main cause of growth decline is a lack of awareness about the use of early toxicity.

COVID-19 Impact on Early Toxicity Testing Market Growth

The quick emergence of COVID-19 has significantly increased demand for the early toxicity testing sector. Toxicity testing examines if a substance is poisonous to living or non-living organisms. The process of determining the degree of tissue or cell damage and the ideal safe dose of any chemical or treatment is known as early toxicity testing. Scientists have discovered two new drugs to prevent COVID-19 infection and treat those exposed to the novel coronavirus. Peptide-based medicines developed by researchers at Australia's QIMR Berghofer Medical Research Institute are being tested in hamsters at IDMIT, a preclinical and clinical research facility in France. To boost vaccine effectiveness, the first peptide-based drug would be provided before viral exposure. The second treatment, on the other hand, would prevent the virus from spending time in previously infected cells. The peptide-based medications were discovered when researchers discovered a previously unknown method of entry for SARS-CoV-2, the virus that causes COVID-19.

Early Toxicity Testing Market Segmentation

The in vitro segment is expected to grow at the fastest CAGR during the forecast period (2024-2031)        

The section is separated into three different types based on technique: in vivo, in vitro, and silica. In 2020, the in vitro category was the greatest contributor to the early toxicity testing market, and it is predicted to maintain its dominance throughout the analysis period. In vitro, toxicity approaches employ a variety of laboratory procedures and cell lines to examine the potentially detrimental effects of various medications and substances on human health. The cost-effectiveness of this technique, technical innovation, and tight regulations for animal use during diagnostic processes all contribute significantly to the growth of the early toxicity testing industry.

Furthermore, market growth is fueled by introducing new products into the market. For example, in Jan 2018, Agilent Technologies Inc. acquired Luxcel Biosciences, a provider of in vitro cell test kits based on real-time fluorescence plate readers situated in Cork, Ireland. This acquisition elevates Agilent's cell analysis line by including simple assay kits compatible with industry-standard plate readers. As a result, various market players' number of regulatory authority approvals for products is boosting market growth.

Early Toxicity Testing Market Geographical Share

North America region holds the largest market share of the global early toxicity testing market

North America is the most important market for early toxicity testing. This can be linked to the USFDA's strict laws controlling product safety evaluation, significant R&D funds, the existence of top toxicology testing service provider CROs in the region, and strong consumer awareness about product safety.

In addition, organic and inorganic strategies such as mergers and acquisitions and partnerships within key market players will strengthen their product portfolio in the studied market which will drive the market. Also, several product launches in the market will lead to lucrative growth of the market. For instance, In February 2018, Charles River Laboratories Inc, an American company specializing in preclinical and clinical laboratory acquisitions, paid USD 800 million for MPI research. Furthermore, advancements in various early toxicity testing techniques from established key players, in the United States, are likely to drive the market growth in North America.

Early Toxicity Testing Companies and Competitive Analysis

The early toxicity testing market is a moderately competitive presence of local as well as global companies.  Some of the key players which are contributing to the growth of the market include Agilent Technologies, Bruker Corporation, Eurofins Scientific, GE Healthcare, Thermo Fisher Scientific, Envigo, Merck, SGS, WuXi AppTec, and Quest Laboratories, among others.

The key players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the Early Toxicity Testing market globally. For instance, in February 2021, the ratings of QUEST Diagnostics Incorporated and other ratings about the same analytical unit have been reviewed by New York Investor Moody's Service. At a portfolio review discussion on February 01, 2021, Moody's assessed the adequacy of the ratings in light of the applicable primary methodology, recent events, and comparing the financial and operating characteristics to similarly rated peers.

GE Healthcare

Overview:

GE Healthcare, a global leader in medical technology and digital solutions, helps doctors to make faster, more informed decisions with intelligent devices, data analytics, applications, and services powered by its Edison intelligence platform.

Product Portfolio:

Cytiva: CytivaTM hESC-derived Cardiomyocyte toxicity assays from GE Healthcare and uncover novel biological biomarkers for cardiotoxicity. The cooperation brings together Genentech's toxicology expertise, experience with primary cardiomyocytes, a library of reference drugs, and GE Healthcare's Cytiva Cardiomyocytes and IN Cell Analyzer high-content analysis (HCA)imaging system. So far, GE Healthcare's Cytiva Cardiomyocytes have been blind-tested against 26 recognized drugs having preclinical and clinical cardiac discordances.